Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
US11980621B2 · kind B2 · utility
1Cited by
4References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 5, 2018 |
| Grant date | May 14, 2024 |
| Priority date | — |
| Expiry date | Mar 12, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P15/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides methods of treating endometriosis in a patient by administration of a gonadotropin-releasing hormone (GnRH) antagonist, for instance, according to dosing regimens predicated on the patient's level of anti-Müllerian hormone (AMH) or β17-estradiol (E2).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.